Zhongwu Lai

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Abstract 6725: AI-derived H&E biomarkers predict differential survival under immunotherapy vs chemotherapy in phase-3 metastatic NSCLC study NEPTUNE.

  Cancer Research · 2026-04-03

• Author Correction: Phenome-wide analysis of copy number variants in 470,727 UK Biobank genomes

  Nature · 2026-03-31

• Phenome-wide analysis of copy number variants in 470,727 UK Biobank genomes

  Nature · 2026-02-04

• Prediction of intraductal cancer microinfiltration based on the hierarchical fusion of peri-tumor imaging histology and dual view deep learning

  BMC Cancer · 2025-10-14

• Association of post-surgical MRD status with neoadjuvant ctDNA dynamics, genomic mutations, and clinical outcomes in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial.

  Journal of Clinical Oncology · 2025-05-28 · 8 citations

• An artificial intelligence-based model for prediction of clonal hematopoiesis variants in cell-free DNA samples

  npj Precision Oncology · 2025-05-20 · 6 citations

• Supplementary Figure S1 from Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor OutcomesPreprint

  2025-05-15

• Supplementary Figure S2 from Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor OutcomesPreprint

  2025-05-15

• Data from Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor OutcomesPreprint

  2025-05-15

• Supplementary Figure S4 from Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor OutcomesPreprint

  2025-05-15

• Supplementary Figure S5 from Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor OutcomesPreprint

  2025-05-15

• Supplementary Figure S3 from Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor OutcomesPreprint

  2025-05-15

• Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes

  Clinical Cancer Research · 2025-03-13 · 3 citations

• Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib

  Genome Medicine · 2024-12-18 · 14 citations

• An artificial intelligence-based model for prediction of Clonal Hematopoiesis mutants in cell-free DNA samplesPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2024-12-16 · 1 citations

• Supplementary Table S5 from Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

  2024-11-05

• Supplementary Figure S7 from Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational BurdenPreprint

  2024-11-05

• Supplementary Table S1 from Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

  2024-11-05

• Supplementary Figure S8 from Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational BurdenPreprint

  2024-11-05

• Supplementary Table S4 from Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

  2024-11-05